About: pharmaceutical strategy

Special ReportOpinionPromoted content
Health 16-12-2020

Pharmaceutical Strategy must do more to support nanomedicines

The EU’s Pharmaceutical Strategy must do more to support nanomedicines and protect patient safety. Here’s why. Mike Isles is the Executive Director of the European Alliance for Access to Safe Medicines (EAASM). If Europe is to make its world-leading pharmaceutical...
Health 26-11-2020

Commission slows down on returning drug manufacturing to Europe

Despite widespread hopes for a quick shift towards 'strategic autonomy', the European Commission has made clear it needs another two years of reflection before coming up with proposals to reduce the risk of shortages caused by over-reliance on third-country medicine production.
Health 25-11-2020

EU ponders new incentives for novel antibiotics

The European Commission will examine specific incentives and a new pricing system to develop innovative antibiotics in its pharmaceutical strategy, in a bid to take a more ambitious stance against the rising threat of anti-microbial resistance (AMR).
Health 03-11-2020

Report: Without orphan drugs law, 2mn patients deprived access to therapies

In the absence of the EU orphan drugs regulation, which focuses on rare diseases, approximately two million patients would not get access to therapies, a new industry-funded report has found.
Health 28-08-2020

EU health agenda: More than Corona

The EU executive is expected to finally get to the heart of its five-year health agenda with the unveiling of Europe's Beating Cancer Plan and the much-awaited pharmaceutical strategy. The launch of both initiatives was confirmed for the fourth quarter of 2020 in the Commission's latest working programme.
Special ReportOpinionPromoted content
Health 13-07-2020

The complexity of R&D for orphan medicines

There are multiple challenges inherent to drug development for rare diseases, all consequences of the small number of patients. For most of these diseases, the body of pre-existing knowledge is extremely limited with a lack of crucial information such as...
Special ReportOpinionPromoted content
Health 10-07-2020

From pandemic to rare disease, medical innovation is the answer

Living through a global pandemic, we can take some comfort from the enormous collaborative research and development response that is taking place to find a way out from under the shadow of the COVID-19 crisis. Scientists around the world are...
Health 07-07-2020

EURORDIS: Rare diseases need more centralised processes within the EU

Future improvement of the EU Orphan Medicines Regulation (OMP) could involve more centralised processes for all rare diseases at the EU level, the European Organisation for Rare Diseases  (EURORDIS) told EURACTIV in a written interview.
Health 06-07-2020

Commission’s ‘risky’ move to re-visit orphan drugs regulation

The European Commission is expected to present by the end of July an evaluation study on the pros and cons of the application of orphan and paediatric regulations, which deal with a niche segment of rare diseases that affect fewer than five in 10,000 people.
Health 22-04-2020

Commission aims to bring back medicine production to Europe

The EU needs to focus on ways to bring the production of medicines and pharmaceutical ingredients back to Europe to avoid a future recurrence of shortages experienced during the COVID-19 crisis, the EU health boss Stella Kyriakides told MEPs on Tuesday (22 April).
Contribute